Davis Polk advised the representatives of the several underwriters in connection with the initial public offering of 69,000,000 shares of Class A common stock of Maravai LifeSciences Holdings, Inc. at $27.00 per share (which includes the exercise in full by the underwriters of their option to purchase up to 9,000,000 additional shares), for total gross proceeds of $1.863 billion. Maravai’s Class A common stock is listed on the Nasdaq Global Select Market under the symbol “MRVI.”
Maravai is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics, novel vaccines and support research on human diseases. Maravai’s products address the key phases of biopharmaceutical development and include complex nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. Maravai LifeSciences is headquartered in San Diego, California.
The Davis Polk corporate team included partner Alan F. Denenberg, counsel Jeffrey Gould and associates Jonathan Bye and Lawrence Edward Traylor Jr. Partner Michael Farber and associate Eitan Ulmer provided tax advice. Partner David R. Bauer and associate Tilak Koilvaram provided intellectual property advice. Counsel Marcie A. Goldstein provided FINRA advice. Associate Brantley Hawkins provided 1940 Act advice. Members of the Davis Polk team are based in the Northern California and New York offices.